Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients

Neoplasma

Volumn 60, Issue 2, 2013, Pages 151-159

  Halamkova, J ^a   Kiss, I ^a   Pavlovsky, Z ^b   Tomasek, J ^a   Jarkovsky, J ^a   Cech, Z ^b   Bednarova, D ^c   Tucek, S ^a   Hanakova, L ^b   Moulis, M ^b   Zavrelova, J ^b   Man, M ^b   Benda, P ^b   Robek, O ^b   Kala, Z ^b   Penka, M ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c GeneProof As   (Czech Republic)

Author keywords

675 4G 5G gene polymorphism; Gastrointestinal cancer; Plasminogen activator inhibitor 1; Plasminogen activator system

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; OXALIPLATIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL EVALUATION; COLORECTAL CARCINOMA; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOMETRY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TUMOR LOCALIZATION; VERY ELDERLY; BLOOD; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MORTALITY;

COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC;

EID: 84878779079     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_020     Document Type: Article

References (64)

1. BRUMMEL-ZIEDINS K, ORFEO T, SWORDS JENNY N, et al. Blood coagulation and fibrinolysis. In: Greer JP, Foerster J, Rodgers JM, et al. editors. Wintrobe's Clinical Hematology, 12th ed. Baltimore: Lippincott Wiliams & Wilkins, 2009: 528-619.
2. SCHMITT M, HARBECK M, THOMSSEN C, WILHELM O, MAGDOLEN V et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target therapy. Thromb Haemost 1997; 78: 285-296.
3. PYKE C, KRISTENSEN P, RALFKIAER E, ERIKSEN J, DANØ K et al. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI1 is located in endothelial cells in tumor stroma. Cancer Res 1991; 51: 4067-4071.
4. FAY WP, SHAPIRO AD, SHIH JL, SCHLEEF RR, GINSBURG D et al. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-1733. http://dx.doi.org/10.1056/NEJM199212103272406
5. CARMELIET P, STASSEN JM, SCHOONJANS L, REAM B, VAN DEN OORD JJ et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effect on haemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-2760. http://dx.doi.org/10.1172/JCI116893
6. HILL SA, SHAUGHNESSY SG, JOSHUA P, RIBAU J, AUSTIN RC et al. Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. Blood 1996; 87: 5061-5073.
7. STEFANSSON S, PETICLERC E, WONG MK, McMAHON GA, BROOKS PC et al. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276: 8135-8141. http://dx.doi.org/10.1074/jbc.M007609200
8. STEFANSSON S, LAWRENCE DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-443. http://dx.doi.org/10.1038/383441a0
9. SUGIURA Y, MA L, SUN B, SHIMADA H, LAUG WE et al. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res 1999; 59: 1327-1336.
10. NYKJAER A, CONESE M, CHRISTENSEN EI, OLSON D, CREMONA O et al. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBO J 1997; 16: 2610-2620. http://dx.doi.org/10.1093/emboj/16.10.2610
11. CHAZAUD B, RICOUX R, CHRISTOV C, PLONQUET A, GHERARDI RK et al. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002; 160: 237-246. http://dx.doi.org/10.1016/S0002-9440(10)64367-2
12. BRUCKNER A, FILDERMAN AE, KIRCHHEIMER JC, BINDER BR, REMOLD HG. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res 1992; 52: 3043-3047.
13. KOBAYASHI H, MONIVA N, GOTOH J, SUGIMURA M, TERAO T et al. Role of activated protein C in faciliting basement membrane invasion by tumor cells. Cancer Res 1994; 54: 261-267.
14. PRAUS M, COLLEN D, GERARD RD. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer 2002; 102: 584-591. http://dx.doi.org/10.1002/ijc.10767
15. HARBECK N, SCHMITT M, KATES RE, KIECHLE M, ZEMZOUM I et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002; 3: 196-200. http://dx.doi.org/10.3816/CBC.2002.n.023
16. TAPONECO F, CURCIO C, GIUNTINI A, NARDINI V, FORNACIARI G et al. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplazia and cancer. J Exp Clin Canc Res 2001; 20: 239-246.
17. BAJOU K, NOËL A, GERARD RD, MASSON V, BRUNNER N et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928. http://dx.doi.org/10.1038/nm0898-923
18. DENG C, CURRIDEN SA, WANG S, ROSENBERG S, LOSKUTOFF DJ. Is plasminogen activator inhibitor 1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-1571. http://dx.doi.org/10.1083/jcb.134.6.1563
19. KANSE SM, KOST C, WILHELM OG, ANDREASEN PA, PREISSNER KT et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-353. http://dx.doi.org/10.1006/excr.1996.0144
20. ABE J, URANO T, KONNO H, ERHAN Y, TANAKA T et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999; 86: 2602-2611. http://dx.doi.org/10.1002/(SICI)1097-0142(19991215)86:12<2602::AIDCNCR4>3.0.CO;2-S
21. KWAAN HC, WANG J, SVOBODA K, DECLERCK PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82: 1702-1708. http://dx.doi.org/10.1054/bjoc.2000.1207
22. BALSARA RD, PLOPLIS VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 2008; 100: 1029-1036.
23. The National Center for Biotechnology Information database,[cited 2012-08-07]. Available:.
24. ERIKSSON P, KALLIN B, VAN HOOFT FM, BAVENHOLM P, HAMSTEN A et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. P Natl Acad Sci USA; 92: 1851-1855. http://dx.doi.org/10.1073/pnas.92.6.1851
25. MANSFIELD MW, STICKLAND MH, GRANT PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Haemost 1995; 74: 1032-1034.
26. SU CK, YEH KT, YEH CB, WANG PH, HO ES et al. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer. J Surg Oncol 2011; 104: 755-759. http://dx.doi.org/10.1002/jso.22035
27. CASTELLO R, ESPANA F, VAZQUEZ C, FUSTER C, ALMENAR SM et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006; 117: 487-492. http://dx.doi.org/10.1016/j.thromres.2005.03.025
28. WANG AY, POON P, LAI FM, YU L, CHOI PC et al. Plasminogen activator inhibitor-gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 2001; 59: 1520-1528. http://dx.doi.org/10.1046/j.1523-1755.2001.0590041520.x
29. MANSFIELD MW, STICKLAND MH, GRANT PJ. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost 1997; 77: 357-361.
30. TASSIES D, ESPINOSA G, MUNOZ-RODRIGUEZ FJ, FREIRE C, CERVERA R et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000; 43: 2349-2358. http://dx.doi.org/10.1002/1529-0131(200010)43:10<2349::AID-ANR24>3.0.CO;2-J
31. PEGORARO RJ, RANJITH N. Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction. Cardiovasc J South Afr 2005; 16: 266-270.
32. RUIZ-QUEZADA S, VAZQUEZ-DEL MERCADO M, PARRA-ROJAS I, RANGEL-VILLALOBOS H, BEST-AGUILERA C et al. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 2004; 47: 155-162. http://dx.doi.org/10.1016/j.anngen.2003.12.001
33. HOOPER WC, LALLY C, AUSTIN H, RENSHAW M, DILLEY A et al. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000; 99: 223-230. http://dx.doi.org/10.1016/S0049-3848(00)00236-X
34. FORSTI A, LEI H, TAVELIN B, ENQUIST K, PALMQVIST R et al. Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann Oncol 2007; 18: 1990-1994. http://dx.doi.org/10.1093/annonc/mdm361
35. LOKTIONOV A, WATSON MA, STEBBINGS WS, SPEAKMAN CT, BINGHAM SA et al. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 2003; 189: 189-196. http://dx.doi.org/10.1016/S0304-3835(02)00556-6
36. SMOLARZ B, ROMANOWICZ-MAKOWSKA H, KULIG A. Plasminogen activator inhibitor 1 1334G/A genetic polymorphism in colorectal cancer. Acta Biochim Pol 2003; 50: 489-495.
37. THERASSE P, ARBUCK SG, EISENHAUER EA, WANDERS J, KAPLAN RS et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205-216. http://dx.doi.org/10.1093/jnci/92.3.205
38. HALAMKOVA J, KISS I, PAVLOVSKY Z, JARKOVSKY J, TOMASEK J et al. Clinical Relevance of uPA, uPAR, PAI 1, PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients. Hepatogastroenterology 2011; 58: 1918-1925.
39. WANG L, MADIGAN MC, CHEN H, LIU F, PATTERSON KI et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol 2009; 114: 265-272. http://dx.doi.org/10.1016/j.ygyno.2009.04.031
40. NEKARDA H, SIEWERT JR, SCHMITT M. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343: 117. http://dx.doi.org/10.1016/S0140-6736(94)90845-1
41. ZEMZOUM I, KATES RE, ROSS JS, DETTMAR P, DUTTA M et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-1028. http://dx.doi.org/10.1200/JCO.2003.04.170
42. HILDENBRAND R, SCHAAF A, DORN-BEINEKE A, ALLGAYER H, SUTTERLIN M et al. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009; 24: 869-877.
43. SAKAKIBARA T, HIBI K, KOIKE M, FUJIWARA M, KODERA Y et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005; 93: 799-803. http://dx.doi.org/10.1038/sj.bjc.6602743
44. OHBA K, MIYATA Y, KANDA S, KOGA S, HAYASHI T et al. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005; 174: 461-465. http://dx.doi.org/10.1097/01.ju.0000165150.46006.92
45. PEDERSEN H, GRONDHAL-HANSEN J, FRANCIS D, OSTERLIND K, HANSEN HH et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994; 54: 120-123.
46. KONECNY G, UNTCH M, PIHAN A, KIMMIG R, GROPP M et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001; 7: 1743-1749.
47. MYTNIK M, STASKO J. D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C-role in prothrombotic state of colorectal cancer. Neoplasma 2011; 58: 235-238. http://dx.doi.org/10.4149/neo_2011_03_235
48. WALTZ DA, NATKIN LR, FUJITA RM, WEI Y, CHAPMAN HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 58-67. http://dx.doi.org/10.1172/JCI119521
49. GRONDAHL-HANSEN J, CHRISTENSEN IJ, ROSENQUIST C, BRUNNER N, MOURIDSEN HT et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
50. KNOOP A, ANDREASEN PA, ANDERSEN JA, HANSEN S, LAENKHOLM AV et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77: 932-940. http://dx.doi.org/10.1038/bjc.1998.154
51. ITO H, YONEMURA Y, FUJITA H, TSUCHIHARA K, KAWAMURA T et al. Prognostic relevance of urokinasetype plasminogen actiator (uPA) and plasminogen activator inhibitor PAI 1 and PAI 2 in gastric cancer. Virchows Arch 1996; 427: 487-496. http://dx.doi.org/10.1007/BF00199509
52. ANGENETE E, LANGENSKIOLD M, PALMGREN I, FALK P, ORESLAND T et al. uPA and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome. J Surg Res 2009; 153: 46-53. http://dx.doi.org/10.1016/j.jss.2008.02.043
53. NIELSEN HJ, CHRISTENSEN IJ, SORENSEN S, MOESGAARD F, BRUNNER N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7: 617-623.
54. HERSZENYI L, FARINATI F, CARDIN R, ISTVAN G, MOLNAR LD et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008; 10: 194. http://dx.doi.org/10.1186/1471-2407-8-194
55. ZHANG X, SHU XO, CAI Q, RUAN Z, GAOET YT al. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res 2006; 12: 6037-6042. http://dx.doi.org/10.1158/1078-0432.CCR-05-2851
56. LEI H, HEMMINKI K, JOHANSSON R, ALTIERI A, ENQUIST K et al. PAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Tr 2008; 109: 165-175. http://dx.doi.org/10.1007/s10549-007-9635-3
57. BLASIAK J, SMOLARZ B. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol 2000; 47: 191-199.
58. Li H, SHINOHARA ET, CAI Q, CHEN H, COURTNEY R et al. Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer. Clin Oncol 2006; 18: 333-337. http://dx.doi.org/10.1016/j.clon.2006.02.005
59. VOSSEN CY, HOFFMEISTER M, CHANG-CLAUDE JC, ROSENDAAL FR, BRENNER H. Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol 2011; 29: 1722-1727.
60. PALMIROTTA R, FERRONI P, SAVONAROLA A, MARTINI F, CIATTI F et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009; 124: 403-408. http://dx.doi.org/10.1016/j.thromres.2009.02.014
61. TEE YT, WANG PH, TSAI HT, LIN LY, LIN HT et al. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia. J Surg Oncol 2012; 106: 204-208. http://dx.doi.org/10.1002/jso.23072
62. SU CK, YEH KT, YEH CB, WANG PH, HOET ES et al. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer. J Surg Oncol 2011; 104: 755-759. http://dx.doi.org/10.1002/jso.22035
63. GILABERT-ESTELLES J, RAMON LA, BRAZA-BOILS A, GILABERT J, CHIRIVELLA M et al. Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity. Thromb Res 2012; 130: 242-247. http://dx.doi.org/10.1016/j.thromres.2011.10.007
64. SMOLARZ B, BLASIAK J, KULIG A, ROMANOWICZ-MAKOWSKA H, DZIKI A et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 2001; 20: 247-252.